Vertical Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, has submitted a new drug application to the FDA for RVL-1201, its acquired blepharoptosis treatment candidate, according to a press release.
The once-daily ophthalmic formulation of the direct-acting alpha-adrenergic receptor agonist oxymetazoline is believed to target Müller’s muscle and elevate the upper eyelid, the release said.
“As a potential first-in-class pharmacologic treatment, we believe RVL will provide meaningful benefits to patients around the world,” Brian Markison, CEO of Osmotica
Uncategorized